MedTrace Logo

A Study on the Efficacy and Safety of IPyC for HER2+ MBC

NCT06990347 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2025-05-25

No results posted yet for this study

Summary

Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).

Conditions

Interventions

DRUG

Inetetamab and Pyrotinib Combined with Chemotherapy

Inetetamab and Pyrotinib Combined with Chemotherapy

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2024-08-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06990347 on ClinicalTrials.gov